The Structural Heart and Valve Center at Vanderbilt Heart and Vascular Institute (VHVI) has recently completed multiple groundbreaking transcatheter clinical trial procedures treating severe regurgitation of the mitral and tricuspid valves, a continuation of a decade of research that is revolutionizing the treatment of these conditions.

Vanderbilt researchers used genetics tools and biobanks with linked electronic health records to explore the associations between statins and noncardiovascular diseases.

Researchers at Vanderbilt University Medical Center have identified potential new targets for the prevention of atherosclerosis through the enhancement of autophagy, a natural process for recycling damaged cellular material.

According to an innovative large-scale clinical trial reported last week in the New England Journal of Medicine, a single daily baby aspirin (81 mg) or a single daily adult aspirin (325 mg) are equally safe and effective for prevention of adverse cardiovascular events for patients with established atherosclerotic cardiovascular disease.

Up to 25% of patients with acute heart failure (AHF) face mortality or hospital readmission within one month after being treated in the emergency department (ED).

Thanks to major funding from the National Institutes of Health (NIH), researchers at Vanderbilt University Medical Center have made major inroads in understanding how high-density lipoprotein (HDL), commonly known as good cholesterol, in some cases may actually contribute to the development of atherosclerosis.

The Adult Congenital Heart Association (ACHA) has awarded the Vanderbilt Adult Congenital Heart Program status as an Adult Congenital Heart Disease (ACHD) Accredited Comprehensive Care Center — the first in Tennessee.